Kruse, Thomas
Benz, Caroline http://orcid.org/0000-0002-5166-3598
Garvanska, Dimitriya H.
Lindqvist, Richard
Mihalic, Filip
Coscia, Fabian
Inturi, Raviteja http://orcid.org/0000-0003-1344-3962
Sayadi, Ahmed
Simonetti, Leandro http://orcid.org/0000-0003-1283-9770
Nilsson, Emma
Ali, Muhammad http://orcid.org/0000-0002-8858-6776
Kliche, Johanna
Moliner Morro, Ainhoa
Mund, Andreas http://orcid.org/0000-0002-7843-5341
Andersson, Eva
McInerney, Gerald http://orcid.org/0000-0003-2257-7241
Mann, Matthias
Jemth, Per http://orcid.org/0000-0003-1516-7228
Davey, Norman E.
Överby, Anna K. http://orcid.org/0000-0001-6553-0940
Nilsson, Jakob http://orcid.org/0000-0003-4100-1125
Ivarsson, Ylva http://orcid.org/0000-0002-7081-3846
Funding for this research was provided by:
Vetenskapsrådet (2020-01541, 2020-04395, 2017-02438, 2018-05851, 2020-03380)
Stiftelsen för Strategisk Forskning (SB16-0039, SB16-0039)
Cancer Research UK (C68484/A28159)
Article History
Received: 9 June 2021
Accepted: 6 October 2021
First Online: 19 November 2021
Competing interests
: J.N. is on the scientific advisory board for Orion Pharma. The other authors declare no competing interests.